

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

4821-362

SERIAL NO.

09/447,218

APPLICANT

A. Aberg et al. (Divisional of Appln. No. 09/039,260)

FILING DATE

Concurrently Herewith

GROUP

1623

Art. Unit

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA		5,595,997	1/97	Aberg et al.	514	290	
AB		5,089,496	2/92	Piwinski et al.	514	253	
AC		5,019,591	5/91	Gardner et al.	514	461	
AD		4,777,170	10/88	Heinrich	514	226.2	
AE		4,659,716	4/87	Villani et al.	514	290	
AF		4,282,233	8/81	Villani	424	267	
AG		3,940,485	2/76	Levinson et al.	424	250	
AH		3,598,123	8/71	Zaffaroni	128	268	
AI		3,536,809	10/70	Applezweig	424	28	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
AJ		WO 92/11034	7/92	PCT	-----	-----		
AK		WO 92/00293	1/92	PCT	-----	-----		
AL		0 288 640	11/88	EPA	-----	-----		
AM		WO 85/03707	8/85	PCT	-----	-----		
AN		WO 96/20708	7/96	PCT	-----	-----		
AO		WO 92/20377	11/92	PCT	-----	-----		


## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AP !		Babe et al., 1996, "Histamine, Bradykinin, and Their Antagonists", <u>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</u> , 9th ed., pp. 581-593 and 598-599
AQ !		McCue, J., 1996, "Safety of Antihistamines in the Treatment of Allergic Rhinitis in Elderly Patients", <u>Arch. Fam. Med.</u> 5:464-468
AR !		Andersen et al., 1995, "Adverse Drug Interactions Clinically Important for the Dermatologist", <u>Arch. Dermatol.</u> 131:468-473
AS !		Peggs et al., 1995, "Antihistamines: The Old and The New", <u>American Family Physician</u> 52(2):593-600
AT !		Berthon et al., 1994, "In Vitro Inhibition, by Loratadine and Descarboxyethoxloratadine, of Histamine Release from Human Basophils, and of Histamine Release and Intracellular Calcium Fluxes in Rat Basophilic Leukemia Cells (RBL-2H3)", <u>Biochemical Pharmacology</u> 47(5): 789-794
AU !		Brandes et al., 1994, "Enhanced Cancer Growth in Mice Administered Daily Human-Equivalent Doses of Some H <sub>1</sub> -Antihistamines: Predictive In Vitro Correlates", <u>J. Nat. Can. Inst. Reports</u> 86(10): 770-775

\*\* Duplicate of reference already of record on PTO-892.

<i>Me</i>	AV !	Kleine-Tebbe et al., 1994, "Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H <sub>1</sub> -antagonist, desethoxycarbonyl-loratadine", J. Allergy Clin. Immunol. <u>93(2):494-500</u>
<i>Me</i>	AW !	Miadonna et al., 1994, "Inhibitory Effect of the H <sub>1</sub> Antagonist Loratadine on Histamine Release from Human Basophils", Int. Arch. Allergy Immunol. <u>105:12-17</u>
<i>Me</i>	AX !	Simons, F.E.R., 1994, "H <sub>1</sub> -Receptor Antagonists Comparative Tolerability and Safety", Drug Safety <u>10(5):350-380</u>
<i>Me</i>	AY !	Zhong et al., 1994, "HPLC-Bestimmung Von Loratadin und seinem aktiven Metaboliten Descarboethoxyloratadin in Humanplasma", Pharmazie <u>49(10):736-739</u> (English abstract attached)
<i>Me</i>	AZ !	Quercia et al., 1993, "Focus on loratadine: A new second-generation nonsedating H <sub>1</sub> -receptor antagonist", Hosp. Formul. <u>28:137-149</u> , 153
<i>Me</i>	BA !	Lavrijsen et al., 1993, "The Interaction of Ketoconazole, Itraconazole and Erythromycin With the In Vitro Metabolism of Antihistamines in Human Liver Microsomes", Abstract 1233 Eur. J. Allergy Clin. Immunol. <u>48(Suppl. 16):34</u>
<i>Me</i>	BB !	Roman et al., 1993, "Loratadine A Review of Recent Findings in Pharmacology, Pharmacokinetics, Efficacy, and Safety, with a Look at Its Use in Combination with Pseudoephedrine", Clinical Reviews in Allergy <u>11:89-110</u>
<i>Me</i>	BC !	Van Peer et al., 1993, "Ketoconazole Inhibits Loratadine Metabolism in Man", Abstract 1234 Eur. J. Allergy Clin. Immunol. <u>48(Suppl. 16):34</u>
<i>Me</i>	BD !	Product Insert CR-318/17597400 7/93 Schering Corporation (1992, 1993)
<i>Me</i>	BE !	Brandes et al., 1992, "Stimulation of Malignant Growth in Rodents by Antidepressant Drugs at Clinically Relevant Doses", Cancer Research <u>52:3796-3800</u>
<i>Me</i>	BF !	Kaliner, M., 1992, "Nonsedating Antihistamines: Pharmacology, Clinical Efficacy and Adverse Effects", American Family Physician <u>45(3):1337-1342</u>
<i>Me</i>	BG !	Knowles, 1992, "Astemizole and Terfenadine - Induced Cardiovascular Effects", Canadian J. Hosp. Pharm. <u>45(1):33, 37</u>
<i>Me</i>	BH !	Parkinson et al., 1992, "Evaluation of Loratadine as an Inducer of Liver Microsomal Cytochrome P450 In Rats and Mice", Biochemical Pharmacology <u>43(10):2169-2180</u>
<i>Me</i>	BI !	Van Cauwenberge, P., 1992, "New Data on the Safety of Loratadine", Drug Invest. <u>4(4):283-291</u>
<i>Me</i>	BJ !	Barnett et al., 1991, "Pharmacology of Non-Sedating H <sub>1</sub> Antihistamines", New Perspectives in Histamine Research pp. 181-196
<i>Me</i>	BK !	"Antihistamines", 1990, Chapter 16 <u>Side Effects of Drugs Annual 14:135-138</u> Elsevier Science Publishers
<i>Me</i>	BL !	Gengo, F.M, 1990, "Dilemma: Antihistamine Selection: Use vs. Side Effects", U.S. Pharmacist pp. 59-72, 92
<i>Me</i>	BM !	Clissold et al., 1989, "Loratadine A Preliminary Review of its Pharmacodynamic Properties and Therapeutic Efficacy", Drugs <u>37:42-57</u>
<i>Me</i>	BN !	"Antihistamines", 1988, Chapter 16 <u>Side Effects of Drugs Annual 12:142-143</u> Elsevier Science Publishers
<i>Me</i>	BO !	Simons et al., 1988, "Astemizole - Induced Torsades de Pointes", Lancet p. 624

! Month of publication data is unavailable for this reference.

Me	BP !	Temple et al., 1988, "Loratadine, an Antihistamine, Blocks antigen- and Ionophore - Induced Leukotriene Release From Human Lung In Vitro", Prostaglandins <u>35(4)</u> :549-554
Me	BQ !	Hilbert et al., 1987, " Pharmacokinetics and Dose Proportionality of Loratadine", J. Clin. Pharmacol. <u>27</u> :694-698
Me	BR !	Craft, 1986, "Torsade de Pointes After Astemizole Overdose", British Med. J. <u>292</u> :660
Me	BS !	Barnett et al., 1984, " Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine", Agents and Actions <u>14(5/6)</u> :590-597
Me	BT !	Wood, 1979, "Antimotion Sickness and Antiemetic Drugs", Drugs <u>17(17)</u> :471-479
Me	BU !	Cohen et al., 1972, "Meclizine and Placebo in Treating Vertigo of Vestibular Origin", Arch. Neurol. <u>27</u> :129-135
Me	BV !	Goodman and Gilman's, 1996, <u>The Pharmacological Basis of Therapeutics</u> , 9th Ed. p. 148, 588-592
Me	BW !	Carmeliet, 1992, "Voltage- and Time-Dependent Block of the Delayed K <sup>+</sup> Current in Cardiac Myocytes by Dofetilide", J. Pharmacol. Exper. Ther. <u>262</u> :809-817
Me	BX !	Lunde, I., 1990, "Antihistamines", Side Effects of Drugs <u>14</u> :135-138
Me	BY !	Dukes, M.N.G. et al., 1988, "Side Effects of Drugs Annual 12", Elsevier Science Publishers B.V. pp. 142-143
Me	BZ !	Ebert, W., 1977, "Soft Elastic Gelatin Capsules: A Unique Dosage Form", Pharmaceutical Technology <u>1</u> :44-50
Me	CA !	Petrin, A., 1974, "Motion Sickness and its Treatment", <i>Schweiz. Med.</i> <u>63</u> :79-81
Me	CB !	Wood, C.D. et al., 1987, "Mechanisms of Antimotion Sickness Drugs", <i>Aviation, Space, and Envir. Med.</i> pp. A262-A265
EXAMINER L. E. Crane 		DATE CONSIDERED 03/21/00
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

! Month of publication data is unavailable for this reference.